FrancophonIA/ELRC3.0 huggingface dataset:
English: Treatment of patients with Child-Pugh C hepatic impairment is not recommended (see Section 5.2).
Maltese: Trattament ta' pazjenti b'indeboliment tal-fwied Child Pugh C mhijiex irrakkomandata (ara Sezzjoni 5.2).
English: The physician educational material should contain:
Maltese: Il-materjal edukattiv għall-pazjent:
English: Fatigue, dizziness, dehydration, and syncope have been reported as adverse reactions with neratinib.
Maltese: Ġew irrappurtati għeja, sturdament, deidrazzjoni u sinkope bħala reazzjonijiet avversi b'neratinib.
English: • Permanently discontinue Nerlynx • Evaluate alternative causes
Maltese: • Waqqaf Nerlynx għalkollox • Evalwa l-kawżi alternattivi
English: The excretion was rapid and complete, with the majority of the radioactivity (61%) recovered within 96 hours and 98% recovered after 10 days.
Maltese: L-eskrezzjoni kienet rapida u sħiħa, bil-maġġoranza tar-radjuattività (61%) irkuprata fi żmien 96 siegħa u 98 % irkuprata wara 10 ijiem.
English: Approximately 10% of patients had Stage I tumours, approximately 40% had Stage II tumours and approximately 30% had Stage III tumours.
Maltese: Madwar 10 % tal-pazjenti kellhom tumuri fi Stadju I, madwar 40 % kellhom tumuri fi Stadju II u madwar 30 % kellhom tumuri fi Stadju III.
English: The patient educational material:
Maltese: Kategorija farmakoterapewtika:
English: Studies in animals have shown embryo-foetal lethality and foetal morphological anomalies (see Section 5.3).
Maltese: Studji f'annimali wrew letalità embrijofetali u anomaliji morfoloġiċi fetali (ara Sezzjoni 5.3). Ir-riskju potenzjali għall-bnedmin mhuwiex magħruf.
English: It appeared that the inhibitory effect of neratinib was primarily on P-gp activity in the gastrointestinal tract as a result of pre-systemic inhibition.
Maltese: Deher li l-effett inibitorju ta' neratinib kien primarjament fuq l-attività ta' P-gp fl-apparat gastrointestinali bħala riżultat ta' inibizzjoni presistemika.
English: How to take Nerlynx
Maltese: Doża ta' Nerlynx
English: Dose reductions occurred in 24.7% of Nerlynx-treated patients.
Maltese: It-tnaqqis fid-doża seħħ f'24.7 % tal-pazjenti ttrattati b'Nerlynx.
English: In particular tell your doctor or pharmacist if you are taking any of the following medicines: - ketoconazole or fluconazole - medicines for fungal infections - erythromycin or clarithromycin - medicines for bacterial infections - rifampicin - a medicine for tuberculosis (TB) - protease inhibitors - antiviral medicines - carbamazepine, phenobarbital, or phenytoin - medicines for seizures - St John's wort - an herbal product for depression - diltiazem or verapamil - medicines for high blood pressure and chest pain - digoxin - a medicine for heart problems - medicines for stomach problems such as:
Maltese: - diltiazem jew verapamil - mediċini għall-pressjoni għolja tad-demm u wġigħ fis-sider - digoxin - mediċina għal problemi tal-qalb - mediċini għal probemi tal-istonku bħal: - lansoprazole, omeprazole jew mediċini simili msejħa “inibituri tal-pompa tal-proton” jew PPIs u ranitidine, cimetidine jew mediċini simili msejħa “antagonisti tar-riċettur H2”
English: Proton pump inhibitors, H2-receptor antagonists and antacids Co-administration with proton pump inhibitors (PPIs) and H2-receptor antagonists are not recommended.
Maltese: Inibituri tal-pompa tal-proton, antagonisti tar-riċettur H2 u antaċidi
English: Both rash and nail disorders led to treatment discontinuation in 0.6% of Nerlynx-treated patients.
Maltese: Kemm ir-raxx kif ukoll id-disturbi tad-difer wasslu għal twaqqif tat-trattament f'0.6 % tal-pazjenti ttrattati b'Nerlynx.
English: Nerlynx should be taken with food, preferably in the morning.
Maltese: Nerlynx għandu jittieħed mal-ikel, preferibbilment filgħodu.
English: Distribution Binding of neratinib to human plasma proteins, including covalent binding to human serum albumin (HSA), was greater than 98% and independent of concentration.
Maltese: It-twaħħil ta' neratinib mal-proteini fil-plażma tal-bniedem, inkluż twaħħil kovalenti ma' albumina fis-seru tal-bniedem (HRA), kien akbar minn 98 % u indipendenti mill-konċentrazzjoni.
English: The recommended dose of Nerlynx is 240 mg (six 40 mg tablets) taken orally once daily, continuously for one year.
Maltese: Pożoloġija Id-doża rakkomandata ta' Nerlynx hija ta' 240 mg (sitt pilloli ta' 40 mg) li jittieħdu mill-ħalq darba kuljum, kontinwament għal sena.
English: Very Common Muscle spasms
Maltese: Komuni Ħafna Spażmi fil-muskoli
English: Proton pump inhibitors, H2-receptor antagonists and antacids The solubility of neratinib is pH-dependent.
Maltese: Informazzjoni dettaljata dwar dan il-prodott mediċinali tinsab fuq is-sit elettroniku tal-Aġenzija
English: Therefore, women using systemically acting hormonal contraceptives should add a barrier method (see Section 4.6).
Maltese: Għalhekk, nisa li jużaw kontraċettivi ormonali li jaħdmu sistemikament għandhom iżidu metodu ta' kontraċezzjoni barriera (ara Sezzjoni 4.6).
English: In a dose escalation study in healthy volunteers, single oral doses of Nerlynx up to 800 mg were administered.
Maltese: Fi studju ta' eskalazzjoni tad-doża f'voluntiera b'saħħithom, ingħataw dożi orali waħidhom ta' Nerlynx sa 800 mg.
English: Film-coated tablet.
Maltese: - telf fil-piż
English: Left ventricular dysfunction has been associated with HER2 inhibition.
Maltese: Disfunzjoni ventrikolari tax-xellug ġiet assoċjata ma' inibizzjoni ta' HER2.
English: Pharmacokinetic/pharmacodynamic relationship(s)
Maltese: Relazzjoni(-jiet) farmakokinetika(ċi)/farmakodinamika(ċi) Indeboliment tal-kliewi
English: Dose modifications for hepatotoxicity Severity of hepatotoxicity*
Maltese: Severità tat-tossiċità†
English: Use of CYP3A4/P-gp inhibitors If the inhibitor cannot be avoided, reduce Nerlynx dose to 40 mg (one 40 mg tablet) taken once daily with a strong CYP3A4/P-gp inhibitor.
Maltese: Użu ta' inibituri ta' CYP3A4/Pgp Jekk l-inibitur ma jkunx jista' jiġi evitat, naqqas id-doża ta' Nerlynx għal 40 mg (pillola waħda ta'
English: Diarrhoea, vomiting, nausea, abdominal pain, abdominal pain upper, and stomatitis1
Maltese: Dijarea, rimettar, nawsja, uġigħ addominali, uġigħ addominali fin-naħa ta' fuq, u stomatite1
English: 2 Unstratified Cox proportional hazards model 3 Unstratified 2-sided log-rank test for all endpoints, except for CNS recurrence for which Gray's method was used.
Maltese: 3 Test log-rank miż-żewġ naħat mhux stratifikat għall-punti tat-tmiem kollha, ħlief għal rikorrenza ta' CNS li għaliha ntuża l-metodu ta' Gray.
English: • Relevant information of Gastrointestinal toxicity (diarrhoea) (e.g. signs and symptoms to be detailed (seriousness, severity, frequency, time to onset, duration, risks and consequences))
Maltese: • Isem il-prodott, is-sustanza attiva u l-indikazzjoni approvata tal-prodott • Informazzjoni rilevanti dwar it-Tossiċità gastrointestinali (dijarea)” (eż. sinjali u sintomi li għandhom jingħataw dettalji dwarhom (gravità, severità, frekwenza, żmien għall-bidu,
English: The film-coated tablets are red oval shaped and debossed with ‘W104' on one side and plain on the other side.
Maltese: Il-pilloli miksija b'rita huma ħomor b'forma ovali u mnaqqxa b'“W104” fuq naħa waħda u b'xejn fuq in-naħa l-oħra.
English: CARTON AND BOTTLE
Maltese: KARTUNA U FLIXKUN
English: Placebo Better hydroxyl neratinib N-oxide and neratinib bis-N-oxide (M11).
Maltese: Reazzjonijiet avversi għal mediċina minħabba Nerlynx fi studji dwar monoterapija għall-kanċer tas-sifer
English: Nerlynx dose modifications and management - general toxicities* Severity of toxicity†
Maltese: 120 mg kuljum Tabella 2: Modifikazzjonijiet u ġestjoni tad-doża ta' Nerlynx - tossiċitajiet ġenerali*
English: Effects of other substances on neratinib
Maltese: Effetti ta' neratinib fuq sustanzi oħra
English: Patients who are treated concomitantly with therapeutic agents whose metabolism involves P-gp substrates in the gastrointestinal tract should be monitored carefully.
Maltese: Pazjenti li jiġu ttrattatib'mod konkomitanti b'aġenti terapewtiċi li l-metaboliżmu tagħhom jinvolvi substrati ta' P-gp fl-apparat gastrointestinali għandhom jiġu mmonitorjati b'attenzjoni.
English: There were 0.2% of Nerlynx treated patients who experienced Grade 3 nail disorder.
Maltese: Kien hemm 0.2 % ta' pazjenti ttrattati b'Nerlynx li esperjenzaw disturb tad-difer ta' Grad 3.
English: Hazard (95% CI)2 P-value3
Maltese: (N=664) ta' periklu (95% C
English: • Periodic safety update reports
Maltese: • Pakkett ta' informazzjoni għall-pazjent
English: Patients with symptomatic skin and subcutaneous tissue disorders should be carefully monitored (see Section 4.8).
Maltese: Pazjenti b'disturbi sintomatiċi fil-ġilda u fit-tessuti ta' taħt il-ġilda għandhom jiġu mmonitorjati b'attenzjoni (ara Sezzjoni 4.8).
English: Figure 1:
Maltese: Kartuna :
English: No. of Events (Neratinib vs.
Maltese: F'dan il-fuljett
English: Very Common Decreased appetite Common
Maltese: Komuni Ħafna Tnaqqis fl-aptit Komuni
English: Renal failure
Maltese: Neratinib Aħjar
English: Patients who experience ≥ Grade 3 diarrhoea requiring IV fluid treatment or any signs or symptoms of hepatotoxicity, such as worsening of fatigue, nausea, vomiting, jaundice, right upper quadrant pain or tenderness, fever, rash, or eosinophilia, should be evaluated for changes in liver function tests.
Maltese: Pazjenti li jesperjenzaw dijarea ta' ≥ Grad 3 li jkunu jeħtieġu kura ta' fluwidu IV jew kwalunkwe sinjali jew sintomi ta' epatotossiċità, bħal aggravar ta' għeja, nawsja, rimettar, suffejra, uġigħ jew tenerezza addominali fin-naħa ta' fuq tal-lemin, deni, raxx, jew esinofilja, għandhom jiġu evalwati għal bidliet fit-testijiet tal-funzjoni tal-fwied.
English: Paediatric population There is no relevant use of Nerlynx in the paediatric population in the indication breast cancer.
Maltese: M'hemm l-ebda użu rilevanti ta' Nerlynx fil-popolazzjoni pedjatrika fl-indikazzjoni kanċer tas-sider.
English: Distant disease-free survival Time to distant recurrence CNS recurrence
Maltese: Żmien għal rikorrenza distanti
English: Diarrhoea led to hospitalisation in 1.9% of Nerlynx-treated patients.
Maltese: Id-dijarea wasslet għal dħul fl-isptar f'1.9 % tal-pazjenti ttratati b'Nerlynx.
English: Neratinib is extensively metabolised in the liver.
Maltese: Neratinib jiġi metabolizzat b'mod estensiv fil-fwied.
English: Adverse Drug Reaction
Maltese: IL-PRODOTT MEDIĊINALI
English: Diarrhoea generally occurred in the first month, with 83.6% of patients reporting this toxicity in the first week, 46.9% in the second week, 40.2% in the third week and 43.2% in the fourth week (median time to first onset was 2 days).
Maltese: Id-dijarea ġeneralment seħħet fl-ewwel xahar, bi 83.6 % tal-pazjenti jirrappurtaw din it-tossiċità fl ewwel ġimgħa, 46.9 % fit-tieni ġimgħa, 40.2 % fit-tielet ġimgħa u 43.2 % fir-raba' ġimgħa (żmien medjan għall-ewwel bidu kien jumejn).
English: The Cmax of neratinib increased by 3.2 fold and AUC increased by 4.8 fold when coadministered with ketoconazole, compared with neratinib administered alone.
Maltese: Is-Cmax ta' neratinib żdiedet bi 3.2 darbiet u l-AUC tiżdied b'4.8 darbiet meta jingħata flimkien ma' ketoconazole, meta mqabbel ma' neratinib mogħti waħdu.
English: A 6-month carcinogenicity study in Tg.rasH2 transgenic mice and the rat 2-year data showed no signs of carcinogenic potential.
Maltese: Studju ta' 6 xhur dwar karċinoġeniċità fi ġrieden transġeniċi Tg.rasH2 u d-data ta' sentejn dwar ilfirien ma wrew l-ebda sinjali ta' potenzjal karċinoġeniku.
English: Kaplan-Meier plot of disease-free survival - hormone receptor positive population who are less than one year from completion of trastuzumab therapy
Maltese: Figura 1: Plott Kaplan-Meier ta' sopravivenza mingħajr marda - popolazzjoni pożittiva għar-riċettur tal-ormon li fadlilha inqas minn sena biex ittemm terapija bi trastuzumab
English: The full EPAR for Herceptin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The difference was between 4.8 and 11.8% depending on the type of chemotherapy.
Maltese: Id-differenza kienet bejn 4.8 u 11.8% skont it-tip ta' kimoterapija.
English: The active substance in Herceptin, trastuzumab, is a monoclonal antibody.
Maltese: Is-sustanza attiva f'Herceptin, it-trastuzumab, hija antikorp monoklonali.
English: This document is a summary of the European public assessment report (EPAR) for Herceptin.
Maltese: Dan id-dokument huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Herceptin.
English: • metastatic gastric (stomach) cancer, in combination with cisplatin and either capecitabine or 5-fluorouracil (other anticancer medicines).
Maltese: • kanċer fil-kolon metastatiku (stonku), flimkien ma' ċisplatina u jew ma' kapesitabina jew 5-fluorouracil (mediċini oħra kontra l-kanċer).
English: Herceptin is a medicine that contains the active substance trastuzumab.
Maltese: Herceptin huwa mediċina li fiha s-sustanza attiva trastuzumab.
English: The most common or serious side effects with Herceptin are heart problems, infections, lung and blood problems, and reactions related to the way Herceptin is given.
Maltese: L-effetti sekondarji l-aktar komuni b'Herceptin huma problemi bil-qalb, infezzjonijiet, problemi filpulmun u fid-demm u reazzjonijiet marbuta mal-mod kif jingħata Herceptin.
English: Why has Herceptin been approved?
Maltese: Għaliex ġie approvat Herceptin?
English: In metastatic breast cancer, Herceptin given by infusion into a vein has been studied in four main studies: one looked at Herceptin on its own in 222 patients whose previous treatment had failed; two looked at Herceptin in combination with paclitaxel or docetaxel in a total of 657 patients; and one looked at the combination of Herceptin and anastrozole (an aromatase inhibitor) in 208 women who had been through the menopause.
Maltese: Fil-kanċer tas-sider metastatiku, Herceptin li ngħata b'infużjoni fil-vina ġie studjat f'erba' studji prinċipali: wieħed ħares lejn Herceptin waħdu f'222 pazjent li kienu diġà ħadu kura li ma kinitx irnexxiet; tnejn ħarsu lejn Herceptin flimkien ma' paklitaksel jew dosetaksel f'total ta' 657 pazjent; u wieħed ħares lejn il-kombinazzjoni ta' Herceptin u anastrozole (inibitur aromatase) f'208 mara li kienu diġà għaddew mill-menopawsa.
English: In the first study in early breast cancer, 8% of the patients who received Herceptin by infusion into a vein after having completed surgery, chemotherapy and radiotherapy (if applicable) experienced a reappearance of their cancer in the first year of treatment (127 out of 1,693), compared with 13% of the patients who did not receive it (219 out of 1,693).
Maltese: Fl-ewwel studju tal-kanċer tas-sider li jkun għadu fil-bidu, 8% tal-pazjenti li ngħataw Herceptin b'infużjoni fil-vina wara li temmew l-intervent kirurġiku, il-kimoterapija u r-radjuterapija (jekk applikabbli) reġa' feġġilhom il-kanċer fl-ewwel sena ta' kura (127 minn 1,693), meta mqabbel ma' 13% tal-pazjenti li ma rċevewhx (219 minn 1,693).
English: Patients who tolerate the first 90-minute infusion can receive subsequent infusions over 30 minutes.
Maltese: Il-pazjenti li jittolleraw l-ewwel infużjoni ta' 90 minuta jistgħu jirċievu infużjonijiet sussegwenti fuq perjodi ta' 30 minuta.
English: In metastatic gastric cancer, Herceptin given by infusion into a vein in combination with cisplatin and either capecitabine or 5-fluorouracil was compared with the same combination but without Herceptin in one main study involving 594 patients.
Maltese: Fil-kanċer tal-kolon metastatiku, Herceptin li jingħata b'infużjoni fil-vina flimkien ma' ċisplatina u jew kapeċitabina jew 5-fluorouracil tqabbel mal-istess kombinazzjoni iżda mingħajr Herceptin fi studju wieħed prinċipali li involva 594 pazjent.
English: In metastatic gastric cancer, the patients with higher levels of HER2 expression who received Herceptin by infusion into a vein survived for an average of 16.0 months, compared with 11.8 months in those receiving cisplatin and either capecitabine or 5-fluorouracil alone.
Maltese: Fil-kanċer tal-kolon metastatiku, il-pazjenti b'livelli għolja ta' espressjoni HER2 li ngħataw Herceptin b'infużjoni fil-vina għexu medja ta' 16-il xahar, meta mqabbla ma' 11.8 xhur f'dawk li ngħataw ċisplatina u jew kapeċitabina jew 5-fluorouracil waħdu.
English: Herceptin given as an injection under the skin was compared with Herceptin given by infusion into a vein in an additional study involving 596 patients with early breast cancer.
Maltese: Herceptin li jingħata bħala injezzjoni taħt il-ġilda tqabbel ma' Herceptin li jingħata bħala infużjoni filvina fi studju addizzjonali li involva 596 pazjent b'kanċer tas-sider li għadu fil-bidu.
English: In metastatic breast cancer, 15% of the patients whose previous treatment had failed responded to Herceptin given by infusion into a vein.
Maltese: Fil-kanċer tas-sider metastatiku, 15% tal-pazjenti li kienu diġà ħadu kura fil-passat u ma rnexxitx irrispondew għal Herceptin li ngħata b'infużjoni fil-vina.
English: What is the risk associated with Herceptin?
Maltese: Għal x'hiex jintuża Herceptin?
English: For locally advanced breast cancer, giving Herceptin by infusion into a vein before surgery in combination with chemotherapy and then again after surgery on its own resulted in fewer patients dying or having their cancer worsen or reappear over three years: after three years, 65% of patients given Herceptin were still alive without having their cancer worsen or reappear as compared to 52% in patients not given Herceptin.
Maltese: F'kanċer tas-sider li jinsab f'post lokalizzat fi stadju avvanzat, l-għoti ta' Herceptin b'infużjoni fil-vina qabel intervent kirurġiku flimkien mal-kimoterapija kif ukoll waħdu wara lintervent irriżulta f'inqas pazjenti mejta jew li kellhom il-kanċer li reġa' feġġilhom jew qaleb għallagħar fuq perjodu ta' tliet snin: wara tliet snin, 65% tal-pazjenti li ngħataw Herceptin kienu għadhom ħajjin mingħajr ma kellhom il-kanċer jaqleb għall-agħar meta mqabbel ma' 52% tal-pazjenti li ma ngħatawx Herceptin.
English: By attaching to HER2, trastuzumab activates cells of the immune system, which then kill the tumour cells.
Maltese: Billi teħel ma' HER2, it-trastuzumab tattiva ċ-ċelloli tas-sistema immunitarja, li mbagħad joqtlu ċ-ċelloli tattumur.
English: How has Herceptin been studied?
Maltese: Kif ġie studjat Herceptin?
English: What is Herceptin?
Maltese: Kif jaħdem Herceptin?
English: When given as an infusion into a vein, Herceptin is given over 90 minutes every week or every three weeks for breast cancer, and every three weeks for gastric cancer.
Maltese: Meta jingħata bħala infużjoni fil-vina, Herceptin jingħata fuq 90 minuta kull ġimgħa jew kull tliet ġimgħat għall-kanċer tas-sider, u kull tliet ġimgħat għall-kanċer tal-kolon.
English: The levels of the active substance were at least as high as when Herceptin is given by infusion into a vein.
Maltese: Il-livelli tas-sustanza attiva kienu għall-inqas għoljin daqs meta Herceptin jingħata b'infużjoni filvina.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Herceptin on 28 August 2000.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Herceptin fit-28 ta' Awwissu 2000.
English: A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and attach to a specific structure (called an antigen) that is found on certain cells in the body.
Maltese: Antikorp monoklonali huwa antikorp (tip ta' proteina) li jkun imfassal biex jagħraf u jeħel ma' struttura speċifika (imsejħa antiġene) li tinsab f'ċerti ċelloli fil-ġisem.
English: Herceptin was given before surgery and the main measure of effectiveness was response to treatment assessed by measuring the proportion of patients who had no cancerous cells found on examination of the breast removed by surgery.
Maltese: Herceptin ingħata qabel il-kirurġija u l-kejl ewlieni ta' effikaċja kien rispons għall-kura vvalutat permezz ta' kejl talproporzjon tal-pazjenti li ma nstabulhomx ċelloli tal-kanċer waqt l-eżaminazzjoni tas-sider li tneħħa permezz ta' kirurġija.
English: The CHMP decided that Herceptin's benefits are greater than its risks and recommended that it be given marketing authorisation.
Maltese: Is-CHMP iddeċieda li l-benefiċċji ta' Herceptin huma akbar mir-riskji tiegħu u rrakkomanda li jingħata awtorizzazzjoni għat-tqegħid fis-suq.
English: In the study comparing Herceptin given under the skin and by infusion into a vein, some side effects have been reported more frequently with Herceptin given under the skin: infections with or without neutropenia (low levels of neutrophils, a type of white blood cells), heart problems, reactions related to the way Herceptin is given and high blood pressure.
Maltese: Fl-istudju li jqabbel Herceptin li jingħata taħt il-ġilda jew fil-vina, ġew irrappurtati xi effetti sekondarji li huma aktar frekwenti meta Herceptin jingħata taħt il-ġilda: infezzjonijiet kemm b'newtropenija kif ukoll mingħajrha (livelli baxxi ta' newtrofili, tip ta' ċelloli bojod tad-demm), problemi bil-qalb, reazzjonijiet marbuta mal mod kif jingħata Herceptin u pressjoni tad-demm għolja.
English: Trastuzumab also stops HER2 producing signals that cause the tumour cells to grow.
Maltese: It-trastuzumab twaqqaf ukoll l-HER2 milli tipproduċi sinjali li jikkawżaw iċ-ċelloli tat-tumur biex jikbru.
English: Patients receiving Herceptin in combination with anastrozole also lived for longer without their cancer getting worse (4.8 months, on average) than those receiving anastrozole alone (2.4 months, on average).
Maltese: Il-pazjenti li kienu qed jingħataw Herceptin flimkien ma' anastrozole ukoll għexu aktar mingħajr ma l-kanċer qaleb għall-agħar (medja ta' 4.8 xhur) meta mqabbla ma' dawk li kienu qed jirċievu anastrozole waħdu (medja ta' 2.4 xhur).
English: Herceptin can only be used when the cancer has been shown to ‘overexpress HER2': this means that the cancer produces a protein called HER2 in large quantities on the surface of the tumour cells, which makes the tumour cells grow more quickly.
Maltese: Herceptin jista' jintuża biss meta l-kanċer wera li huwa ‘overexpress' HER2 (‘HER2 espressa żżejjed'): dan ifisser li l-kanċer jipproduċi proteina msejħa HER2 fi kwantitajiet kbar fil-wiċċ taċ-ċelloli tat-tumur, li tkabbar iċ-ċelloli tat-tumur aktar malajr.
English: Other information about Herceptin:
Maltese: -Aktar tagħrif dwar Herceptin:
English: Herceptin is used to treat the following types of cancer:
Maltese: Herceptin jintuża fit-trattament tat-tipi ta' kanċer li ġejjin:
English: Black (n=966)
Maltese: Suwed (n=966)
English: Salutas Pharma GmbH Otto-von-Guericke-Allee 1 39179 Barleben Germany
Maltese: Salutas Pharma GmbH Otto-von-Guericke-Allee 1 39179 Barleben Il-Ġermanja
English: EU/1/09/542/001 EU/1/09/542/002 EU/1/09/542/003 EU/1/09/542/004 EU/1/09/542/005 EU/1/09/542/006 EU/1/09/542/007
Maltese: EU/1/09/542/001 EU/1/09/542/002 EU/1/09/542/003 EU/1/09/542/004
English: White (n=1356)
Maltese: Bojod (n=1356)
English: Chinese (n=573)
Maltese: Ċiniżi (n=573)
English: 1A Pharma GmbH Sp. Z.o.o.
Maltese: 1A Pharma GmbH Sp. Z.o.o. ul.
English: Several polymorphic CYP450 enzymes activate Clopidogrel.
Maltese: Ħafna enzimi CYP450 polimorfiċi jattivaw Clopidogrel.
English: The use of Clopidogrel in CURE was associated with a decrease in the need of thrombolytic therapy (RRR = 43.3%; CI: 24.3%, 57.5%) and GPIIb/IIIa inhibitors (RRR = 18.2%; CI: 6.5%, 28.3%).
Maltese: L-użu ta' Clopidogrel fi CURE kien assoċjat mat-tnaqqis fil-bżonn ta' kura trombolitika (RRR = 43.3 %; CI: 24.3 %, 57.5 %) u inibituri ta' GPIIb/IIIa (RRR = 18.2 %; CI: 6.5 %, 28.3 %).
English: Poor metabolism:
Maltese: Metaboliżmu intermedju: